Study Of Intravitreal Injection Of Bevacizumab For Macular Edema Secondary To Retinal Vein Occlusion

Objective To evaluate the therapeutic efficacy of intravitreal injection of Bevacizumab (IVB) in patients with ME secondary to RVO. Moreover, observing the change of early intraocular pressure(IOP).Methods Forty-nine patients (49eyes) with ME secondary to RVO determined by indirect ophthalmoscope, FFA and3D-OCT were selected. The patients were divided into two groups randomly. The two groups were treated routinely with conventional drug therapy, and the test group were received intravitreal injection of Bevacizumab. The average BCVA, IOP, CMT under3D-OCT and the possible complications were recorded and analyzed prior to treatment and lweek,1,3,6months after treatment. The patients in test group were assigned into BRVO group or CRVO group. IOP was measured before injection and30minutes,1,1.5,2hours and1day after injection in test group with non-contact tonometer (Topcon-80).Results The average BCVA in test group was (0.24±0.20) before injection and (0.43±0.20,0.47±0.30,0.41±0.32,0.34±0.34)1week,1,3,6months after injection; the differences were significant (P<0.05). The mean CMT in test group was (500±141μm) before injection and (313±55μm,325±101μm,360±17μm,396±143μm)1week,1,3,6months after injection; the differences were significant (P<0.05). The average BCVA in control group (0.28±0.19,0.29±0.21,0.27±0.27,0.25±0.26)1week,1,3,6months after treatment differed not so much from that (0.25±0.20) before treatment. The mean CMT in control group (446±117μm,447±119μm,443±118μm,449±122μm)1week,1,3,6months after treatment differed not so much from that (457±128μm)before treatment. The average BCVA and CMT at1week,1,3,6months after treatment in test group had statistically significant difference in comparison to the control group (P<0.05). In BRVO group, the average BCVA was significantly increased and CMT was obviously decreased at1month after injection, while at1week after injection in CRVO group. As the average BCVA3months and6months after injection as a standard, the curative effect of IVB in BRVO group has no difference in comparison to CRVO group. The mean maximum IOP was (19.72±8.19mmHg)30minutes after injection in test group, and (]5.35±2.51mmHg) before treatment; the difference was statistically significant (P<0.05). The mean IOP1day after injection was (16.17±3.17mmHg), showing no significant difference in comparison with before treatment. No ocular or systemic adverse events were found after treatment during the follow-up duration.Conclusion In a short-time follow-up, intravitreal injection of bevacizumab is relatively safe and effective for macular edema induced by RVO. Whether BRVO or CRVO, the curative effect of bevacizumab for macular edema is no significant difference. IVB therapy may be shown high intraocular pressure temporarily30minutes after injection, which recovered normal after a local treatment of topical eye drop in24hours.